Prenetics posted record results for Q4 and FY2025, driven by its IM8 consumer health brand. FY2025 revenue rose 479.7% YoY to USD 92.39 million, with gross profit up 427.6% YoY to USD 48.94 million; adjusted EBITDA loss narrowed 27.2% YoY to USD 12.99 million, while loss from continuing operations was USD 54.97 million and net cash used in operating activities was USD 22.90 million. In Q4 2025, revenue increased 457.1% YoY to USD 36.56 million and gross profit rose 801.1% YoY to USD 21.74 million; adjusted EBITDA loss improved 70.4% YoY to USD 2.25 million, while loss from continuing operations was USD 28.41 million. IM8 revenue was USD 27.45 million in Q4 and USD 60.15 million in FY2025, and reached USD 10.00 million in monthly revenue in December 2025, implying ARR of about USD 120 million as of December 2025. IM8 reported Q4 gross margin of about 60%, average order value of USD 133, and a payback period of 3.5 months, with a new-customer subscription rate of about 80%. The company said it completed a strategic transformation with divestitures and a focus on IM8, including the sale of its stake in Insighta to Tencent for USD 70.00 million in cash, and reported total adjusted liquidity of about USD 171.12 million as of Feb. 15, 2026, with no outstanding debt. Prenetics reaffirmed 2026 IM8 revenue guidance of USD 180 million to USD 200 million and outlined a path toward adjusted EBITDA profitability by Q4 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prenetics Global Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9656743-en) on February 18, 2026, and is solely responsible for the information contained therein.